Side-by-side · Research reference

GDF-8vsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/48 cited

BHuman-MechanisticAUTO-DRAFTED11/40 cited

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

GDF-8

Selank

Primary target

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

GDF-8

Selank

Clinical use

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

—

Inhibition strategies

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

—

VLP immunogen (MS2.87-97)

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

—

Dual immunization (MSTN + Activin A)

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

—

Gene editing outcomes

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

—

Standard dose

—

150–300 mcg / dose intranasalZaderej 2014

Frequency

—

2–3× per day during stress

Lower / starter dose

—

75 mcg / dose

Evidence basis

—

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

—

10–14 day cycles, repeated as needed

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon preferred

Half-life

—

Short (minutes plasma); CNS effect lasts ~3 hr

03Metabolic / Fat Loss Evidence

Parameter

GDF-8

Selank

Primary mechanism

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

—

Human genetic evidence

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

—

Animal model outcomes

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

—

Adipose-muscle crosstalk

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

—

Metabolic benefits

Improved metabolic health in genetic MSTN null modelsJacquez 2026

—

Age-related effects

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

—

04Side Effects & Safety

Parameter

GDF-8

Selank

Genetic null phenotype

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

—

Antibody cross-reactivity risk

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

—

VLP immunotherapy safety

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

—

Echocardiography

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

—

Pleiotropic effects (gene editing)

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

—

Assay variability

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

—

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

GDF-8

Selank

1. Research context only

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Inhibition strategies

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. VLP immunization protocol (animal model)

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Gene editing considerations

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Caveat

—

Avoid co-administration with strong sedatives or other anxiolytics initially.